24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol

This is an interventional treatment trial for Glaucoma focused on measuring 24-hour IOP control, brinzolamide/timolol, brimonidine/timolol, travoprost Read More

Inclusion Criteria:

• Patient has open-angle glaucoma and is older than 29 years
• Patients should exhibit typical disc, or field changes and an untreated morning IOP greater than 25 mm Hg
• Patients are treated for at least 3 months with travoprost and should have demonstrated at least a 20% morning IOP reduction
• Patient deemed by PI to require adjunctive therapy to obtain desired target IOP
• Patient should exhibit IOP greater than 18 mm Hg on travoprost monotherapy (2 separate IOP readings at 10:00)
• Patient has mild to moderate glaucoma (field loss more than 16 dB; cupping 0.8 or less)
• Distance best corrected Snellen visual acuity at least 0.1
• No contraindications to travoprost, brimonidine, brinzolamide and β-blockers
• No history of lack of response (<10% morning IOP reduction) to any medication
• Patient can understand the instructions and adhere to medications

Exclusion Criteria:

• Female patient of childbearing potential or lactating mother
• History of trauma, inflammation, surgery
• History of past use of steroids (within 2 months), severe dry eyes and use of contact lenses
• Signs of ocular infection, except blepharitis
• Evidence of corneal abnormality that may affect IOP measurements etc
• Closed angle
• History of non-compliance